Jupiter Neurosciences Announces Board and Executive Changes
Ticker: JUNS · Form: 8-K · Filed: 2025-07-09T00:00:00.000Z
Sentiment: neutral
Topics: management-change, board-composition, executive-compensation
TL;DR
Jupiter Neurosciences shakes up its board and exec team, new hires and comp plans announced.
AI Summary
Jupiter Neurosciences, Inc. announced on July 2, 2025, changes in its board and executive team, including the election of new directors and the appointment of certain officers. The company also reported on compensatory arrangements for its key executives. This filing details the composition of the board and the compensation structures for its leadership.
Why It Matters
Changes in board and executive leadership can signal shifts in company strategy, operational focus, or financial direction, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in executive and board composition can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- JUPITER NEUROSCIENCES, INC. (company) — Registrant
- Jupiter Orphan Therapeutics, Inc. (company) — Former company name
- 20250702 (date) — Date of earliest event reported
- July 2, 2025 (date) — Date of Report
- 1001 North US HWY 1 (address) — Principal executive offices
- Jupiter, FL 33477 (address) — Principal executive offices location
- (561) 406-6154 (phone_number) — Business phone number
FAQ
What specific roles were filled or changed among the officers?
The filing indicates the appointment of certain officers and changes in executive positions, but specific names and titles of newly appointed officers are not detailed in the provided text.
Were there any new directors elected to the board?
Yes, the filing states the election of directors as an item of information, implying new board members or changes to the existing board composition.
What is the effective date of these board and executive changes?
The date of the earliest event reported is July 2, 2025.
What is the primary business of Jupiter Neurosciences, Inc.?
Jupiter Neurosciences, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Where are Jupiter Neurosciences, Inc.'s principal executive offices located?
The principal executive offices are located at 1001 North US HWY 1, Suite 504, Jupiter, FL 33477.
From the Filing
0001641172-25-018429.txt : 20250709 0001641172-25-018429.hdr.sgml : 20250709 20250709164039 ACCESSION NUMBER: 0001641172-25-018429 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250702 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250709 DATE AS OF CHANGE: 20250709 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JUPITER NEUROSCIENCES, INC. CENTRAL INDEX KEY: 0001679628 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 474828381 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41265 FILM NUMBER: 251114012 BUSINESS ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: (561) 406-6154 MAIL ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 FORMER COMPANY: FORMER CONFORMED NAME: Jupiter Orphan Therapeutics, Inc. DATE OF NAME CHANGE: 20160713 8-K 1 form8-k.htm 8-K false 0001679628 0001679628 2025-07-02 2025-07-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   July 2, 2025 Date of Report (Date of earliest event reported)   JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware 001-41265   47-4828381 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   1001 North US HWY 1 , Suite 504 , Jupiter , FL   33477 (Address of principal executive offices)   (Zip Code)   (561) 406-6154 Registrant’s telephone number, including area code   Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock   JUNS   Nasdaq Capital Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging Growth Company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers   Approval of Bonus Package to Executive Officers   On July 2, 2025, the Compensation Committee of the board of directors (the “Compensation Committee”) of Jupiter Neurosciences, Inc. (the “Company”), after review of the Company’s Final 2025 Budget, approved a bonus package to compensate certain officers of the Company for their role in